Trials / Unknown
UnknownNCT05664386
Effect of Ciprofol Infusion for Induction and Maintenance on Hemodynamics and Postoperative Recovery
Effect of Ciprofol Infusion for Induction and Maintenance on Hemodynamics and Postoperative Recovery in Patients Undergoing Thoracoscopic Lobectomy : a Randomized, Controlled Trial
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 126 (estimated)
- Sponsor
- Xiumei Song · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To study the Effect of Ciprofol Infusion for Induction and Maintenance of anesthesia on Hemodynamics and Postoperative Recovery in Patients Undergoing Thoracoscopic Lobectomy:a randomized, controlled trial.
Detailed description
Patients undergoing Thoracoscopic Lobectomy aged 18\~65 years old were randomly assigned to Group P and Group C . Group P was given propofol 2 \~ 2.5mg/kg, group C was given ciprofol 0.4 \~ 0.5mg/kg, if bispectral index(BIS) value ≤60 during anesthesia induction, cisatracurium 0.2mg/kg and sufentanil 0.5μg/kg were injected intravenously, endotracheal intubation was performed after the improvement of muscle relaxation. If the BIS value was greater than 60, propofol was added intravenously 1mg/kg each time or ciprofol 0.2mg/kg each time, and the interval of administration was greater than 1min, until BIS≤60. Cisatracurium and sufentanil were injected intravenously, followed by endotracheal intubation.Then propofol was maintained in group P at 4-12 mg/kg/h and remifentanil was maintained at 0.1-0.3 ug/kg/min .Ciprofol was maintained in Group C at 0.8-2.5 mg/kg/h and remifentanil was maintained at 0.1-0.3 ug/kg/min . Intermittent addition of cisatracurium. Sufentanil was added as required, and total dosage of Sufentanil was 0.7ug \~ 1ug/kg. BIS was kept at 40 \~ 60 during the surgery, and infusion drugs were stopped at the end of the operation. The patients were Transfer to Postanesthesia care unit(PACU) after the operation. The primary outcomes were the fluctuations in hemodynamic parameters during induction and the surgery. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MAP),heart rate (HR) and BIS values at various time points were collected. The secondary outcome were as follows: 1. The time of lose consciousness(LOC) during the induction, The Time and dosage of additional drug, and the BIS value during the induction process. 2. The incidence of adverse events such as injection pain, body movement, muscle twitching, hypotension, hypertension, bradycardia or tachycardia, cough and bronchospasm during induction. 3. quality of recovery 15(QOR15) score at pre-operation(Preop) 、on the first day of postoperation (POD1)and on the second day of postoperation (POD2) . 4. the recovery time of consciousness (ROC), extubation time, PACU stay time, postoperative hospital stay time. 5. Incidence of postoperative nausea and vomiting, incidence of postoperative agitation and delayed recovery, and intraoperative awareness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | propofol | propofol 2~2.5mg/kg was used for anesthesia induction. propofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthesia of induction and maintenance. |
| DRUG | ciprofol | Ciprofol 0.4~0.5mg/kg was used for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid recovery of consciousness, minimal residual effects on the central nervous system and less injection pain. |
Timeline
- Start date
- 2023-04-10
- Primary completion
- 2024-10-31
- Completion
- 2024-12-01
- First posted
- 2022-12-23
- Last updated
- 2024-01-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05664386. Inclusion in this directory is not an endorsement.